Abstract
Portugal has been portrayed as a relatively successful case in the control of the COVID-19’s March 2020 outbreak in Europe due to the timely confinement measures taken. As other European Union member states, Portugal is now preparing the phased loosening of the confinement measures, starting in the beginning of May. Even so, the current data, albeit showing at least a reduction in infection rates, renders difficult to forecast scenarios in the imminent future. Using South Korea data as scaffold, which is becoming a paradigmatic case of recovery following a high number of infected people, we fitted Portuguese data to biphasic models using non-linear regression and compared the two countries. The results, which suggest good fit, show that recovery in Portugal can be much slower than anticipated, with a very high percentage of active cases (over 50%) remaining still active even months after the projected end of mitigation measures. This, together with the unknown number of asymptomatic carriers, may increase the risk of a much slower recovery if not of new outbreaks. Europe and elsewhere must consider this contingency when planning the relief of containment measures.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Applied Molecular Biosciences Unit (UCIBIO) which is financed by national funds from ‘Fundação para a Ciência e a Tecnologia’, FCT (UIDB/04378/2020). AM is supported by CEEC/IND/00175/2017 contract, BioISI (UIDB/04046/2020 and UIDP/04046/2020) and Green-IT (UID/Multi/04551/2013) grants from FCT.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data is provided as Supplementary Material.
